- 4-Week # shares sold: 130,817
- 12-Week # shares sold: 290,817
- 24-Week # shares sold: 300,817
Previously studies already showed improvement from use of Exelixis's Cabometyx over Pfizer's Sutent in treating kidney cancer patients.
Here's what you need to know now for Wed., Aug. 9.
All eyes are on Pfizer in the months ahead.